The Myelin Repair Foundation (MRF) and Endece
Neural established a partnership to progress the latter’s myelin
regeneration drug candidates through preclinical development and into
Phase I studies for the treatment of multiple sclerosis
(MS). Endece Neural is the neurological drug development subsidiary of
Wisconsin-based Endece. As part of the collaboration, the MRF’s newly
established Translational Medicine Center will evaluate the myelin
regenerating capabilities of Endece’s small molecule candidates using MS
models.
Print to Page
Email to a Friend